Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:

Lumos Pharma Inc (LUMO)

Lumos Pharma Inc (LUMO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Lumos: Q2 Earnings Snapshot AP - Thu Aug 1, 3:56PM CDT

Lumos: Q2 Earnings Snapshot

LUMO : 3.70 (-4.64%)
Lumos Pharma Reports Second Quarter 2022 Financial Results and Clinical Development Updates Globe Newswire - Tue Aug 9, 2022

-- Continue to Anticipate Interim Data from Phase 2 OraGrowtH210 and PK/PD OraGrowtH212 Trials in Q4 2022 -- -- Primary Outcome Readouts from Both Trials...

LUMO : 3.70 (-4.64%)
Lumos Pharma to Report Second Quarter 2022 Financial Results and Host Conference Call on August 9, 2022 Globe Newswire - Wed Jul 27, 2022

AUSTIN, Texas, July 27, 2022 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company, today announced it will...

LUMO : 3.70 (-4.64%)
Lumos Pharma to Participate in Upcoming Investor Conferences Globe Newswire - Mon May 16, 2022

AUSTIN, Texas, May 16, 2022 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for...

LUMO : 3.70 (-4.64%)
Lumos Pharma Reports First Quarter 2022 Financial Results and Clinical Development Updates Globe Newswire - Tue May 10, 2022

--Phase 2 OraGrowtH210 Trial Reached 50% Randomization Milestone – Interim Data from Phase 2 and PK/PD OraGrowtH Trials Anticipated by End of 2022-- --FDA...

LUMO : 3.70 (-4.64%)
Lumos Pharma Announces a Clinical Collaboration with Massachusetts General Hospital (MGH) to Evaluate Oral LUM-201 in Nonalcoholic Fatty Liver Disease (NAFLD) in a Phase 2 Investigator-Initiated Trial Globe Newswire - Thu May 5, 2022

The IND application for this pilot trial to evaluate oral growth hormone secretagogue, LUM-201, in NAFLD has been approved by the FDA...

LUMO : 3.70 (-4.64%)
Lumos Pharma to Report First Quarter 2022 Financial Results and Host Conference Call on May 10, 2022 Globe Newswire - Tue Apr 26, 2022

AUSTIN, Tex., April 26, 2022 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company, today announced it will...

LUMO : 3.70 (-4.64%)
Lumos Pharma Reaches 50% Randomization Milestone in Phase 2 OraGrowtH210 Trial Evaluating Oral LUM-201 in PGHD Globe Newswire - Mon Apr 11, 2022

-   Interim Data Anticipated by End of 2022   - -   Interim Data from PK/PD OraGrowtH212 Trial also Anticipated by End of 2022 - AUSTIN, Texas, April ...

LUMO : 3.70 (-4.64%)
Lumos Pharma to Participate in the Cantor Rare Disease Symposium Globe Newswire - Wed Mar 23, 2022

AUSTIN, Texas, March 23, 2022 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics...

LUMO : 3.70 (-4.64%)
Lumos Pharma Reports Full Year 2021 Financial Results and Announces Plan to Perform Interim Analyses of OraGrowtH Trials Globe Newswire - Thu Mar 10, 2022

Data from interim analyses of Phase 2 OraGrowtH210 Trial and PK/PD OraGrowtH212 Trial evaluating oral LUM-201 in PGHD anticipated by the end of 2022...

LUMO : 3.70 (-4.64%)

Barchart Exclusives

3 Top Dividend Stocks to Buy This September Barchart - Wed Sep 18, 6:30PM CDT
After today's jumbo rate cut from the Fed, here are three dividend stocks to bolster your portfolio. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot